How to Get Testosterone Enanthate in Wisconsin

At a glance
- Prescription required / Schedule III controlled substance in Wisconsin
- Telehealth prescribing / legal and active in Wisconsin for testosterone enanthate
- Lab requirement / two morning total testosterone draws below 300 ng/dL per AUA guidelines
- Dose form / intramuscular injection, typically 100 to 200 mg weekly
- Wisconsin Medicaid / covered with prior authorization for diagnosed male hypogonadism
- 503A compounding / available through Wisconsin-licensed compounding pharmacies
- Prescribers / MD, DO, NP (with prescriptive authority), and PA can prescribe
- DEA registration / prescriber must hold active DEA Schedule III authority
- Delivery timeline / 3 to 10 business days from prescription to first injection
- Manufacturer options / multiple FDA-approved generics available
Who Can Prescribe Testosterone Enanthate in Wisconsin
Any Wisconsin-licensed prescriber with DEA Schedule III authority can write a testosterone enanthate prescription. That includes physicians (MD and DO), nurse practitioners with prescriptive authority, and physician assistants practicing under a collaborative agreement.
Wisconsin statute 448.9865 grants advanced practice nurse prescribers (APNPs) independent prescriptive authority for controlled substances after completing required DEA registration. PAs prescribe under physician oversight per Wisconsin Medical Examining Board rules. Both provider types routinely manage testosterone replacement therapy (TRT) in primary care and endocrinology settings across the state.
The Endocrine Society's 2018 clinical practice guideline recommends that prescribers confirm hypogonadism with at least two morning total testosterone measurements below 300 ng/dL before initiating therapy [1]. Wisconsin-based telehealth platforms follow this same diagnostic threshold. A single low reading is insufficient. The guideline also specifies that testosterone should not be prescribed to men actively trying to conceive, given its suppressive effect on spermatogenesis [1].
Urologists and endocrinologists see the most TRT patients in Wisconsin, but family medicine physicians write a significant share of testosterone prescriptions nationally. A 2017 cross-sectional analysis found that primary care providers accounted for roughly 50% of all testosterone prescriptions in the United States [2].
Telehealth Access for Testosterone Enanthate in Wisconsin
Wisconsin law permits telehealth prescribing of testosterone enanthate, and multiple platforms currently serve the state. This is the fastest path for most patients.
After the COVID-19 public health emergency accelerated telehealth adoption, Wisconsin codified permanent telehealth parity through Act 56 (signed in 2023), allowing providers to establish a patient-prescriber relationship via synchronous audio-video visits. The DEA's updated telemedicine rules require an initial audio-video evaluation (not audio-only) for Schedule III prescriptions, which testosterone enanthate falls under [3].
A typical telehealth workflow in Wisconsin looks like this: you complete an online intake, get a lab order sent to a local draw site (Quest Diagnostics and Labcorp both operate multiple locations in Milwaukee, Madison, Green Bay, and smaller markets), have a video consultation once results return, and receive a prescription electronically transmitted to your chosen pharmacy. Total time from intake to prescription ranges from 5 to 10 days depending on lab scheduling.
Telehealth platforms vary in cost. Cash-pay monthly programs typically run $99 to $199 per month and bundle the consultation, lab review, and medication. Some platforms ship medication directly from partner pharmacies; others send the prescription to a local retail or compounding pharmacy of your choice.
Required Labs Before Starting Testosterone Enanthate
Wisconsin providers follow the American Urological Association (AUA) 2018 guidelines, which require specific bloodwork before prescribing testosterone [4].
The minimum panel includes two morning total testosterone levels (drawn before 10 AM, on separate days), a complete blood count (CBC) with hematocrit, a comprehensive metabolic panel (CMP), luteinizing hormone (LH), follicle-stimulating hormone (FSH), prolactin, estradiol, and a PSA for men over 40. The AUA guideline defines testosterone deficiency as a total testosterone consistently below 300 ng/dL [4]. Some clinicians also measure free testosterone and sex hormone-binding globulin (SHBG) for a more complete picture.
Hematocrit deserves special attention. The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 and older with testosterone levels below 275 ng/dL, found that testosterone gel increased hemoglobin levels and corrected unexplained anemia in 54% of treated participants versus 15% on placebo [5]. That erythropoietic effect means hematocrit must be monitored at baseline and regularly during treatment. The FDA label for testosterone enanthate includes a boxed warning about polycythemia risk when hematocrit exceeds 54% [6].
Dr. Shalender Bhasin, the principal investigator of TTrials and professor of medicine at Brigham and Women's Hospital, stated: "Testosterone treatment should be accompanied by monitoring of hematocrit, particularly in older men who are at higher cardiovascular risk" [5].
Wisconsin lab draw sites are widespread. Quest Diagnostics operates over 25 patient service centers across the state, and Labcorp maintains a comparable footprint. Smaller independent labs also accept orders from telehealth providers.
Pharmacy Options and 503A Compounding in Wisconsin
Wisconsin patients can fill testosterone enanthate prescriptions at retail chain pharmacies, independent pharmacies, or licensed 503A compounding pharmacies. Each option carries different cost and formulation considerations.
Retail pharmacies (CVS, Walgreens, Walmart, Costco) stock FDA-approved generic testosterone enanthate from manufacturers like Perrigo and Hikma. A 5 mL vial of 200 mg/mL testosterone enanthate (the most common concentration) costs approximately $30 to $80 at retail without insurance, depending on the pharmacy and any discount card used. GoodRx data for Wisconsin zip codes shows prices as low as $25 with coupon at select Costco locations.
503A compounding pharmacies in Wisconsin can prepare testosterone enanthate in custom concentrations or volumes under patient-specific prescriptions. The Wisconsin Pharmacy Examining Board regulates these facilities under Wis. Admin. Code chapter Phar 8. Compounded testosterone may cost $40 to $120 per month depending on concentration, carrier oil (grapeseed and cottonseed are common), and whether the pharmacy ships directly.
A 503A pharmacy can legally ship compounded testosterone enanthate within Wisconsin and, in some cases, to out-of-state patients under federal section 503A of the Food, Drug, and Cosmetic Act. The pharmacy must hold valid Wisconsin licensure and comply with USP 797 sterile compounding standards [7].
For patients who prefer home delivery, several national compounding pharmacies hold Wisconsin non-resident pharmacy licenses and can ship testosterone enanthate directly. Verify that any out-of-state pharmacy appearing on a telehealth platform's website holds a current Wisconsin non-resident license through the Wisconsin Department of Safety and Professional Services (DSPS) license lookup tool.
Wisconsin Medicaid Coverage and Prior Authorization
Wisconsin Medicaid (BadgerCare Plus and fee-for-service) covers testosterone enanthate for diagnosed male hypogonadism, but prior authorization (PA) is required.
The Wisconsin Department of Health Services (DHS) Preferred Drug List classifies testosterone enanthate as a covered injectable androgen. PA approval requires the prescriber to document a confirmed diagnosis of hypogonadism (ICD-10 code E29.1), two lab values showing total testosterone below 300 ng/dL, and the absence of contraindications including breast cancer, untreated polycythemia, or severe untreated sleep apnea [6].
The PA process typically involves submitting a request through the state's pharmacy benefit manager. Turnaround is 24 to 72 hours for standard requests and 24 hours for urgent requests. If denied, the prescriber can file an appeal with additional clinical documentation. Common denial reasons include incomplete lab work, only a single testosterone level on file, or missing documentation of signs and symptoms.
Commercial insurance plans in Wisconsin (Anthem, Quartz, Group Health Cooperative, Dean Health Plan, Network Health) generally cover FDA-approved testosterone enanthate with similar PA requirements. Coverage policies vary by plan, so call the member services number on the back of your insurance card for specifics before filling.
The AUA guideline notes: "Insurance coverage for testosterone therapy remains inconsistent across payers, and prior authorization requirements can delay initiation of treatment by days to weeks" [4].
Dosing and Administration Basics
Standard testosterone enanthate dosing for hypogonadism is 100 to 200 mg administered intramuscularly once weekly or 200 to 400 mg every two weeks. The FDA-approved label recommends 50 to 400 mg every two to four weeks, though most current clinical practice favors weekly injections for more stable serum levels [6].
Weekly dosing produces smaller peaks and troughs compared to biweekly protocols. A pharmacokinetic study published in the Journal of Clinical Endocrinology & Metabolism demonstrated that 100 mg weekly injections maintained serum testosterone within the physiologic range (400 to 700 ng/dL) more consistently than 200 mg every two weeks, which produced supraphysiologic peaks followed by symptomatic troughs [8].
Most Wisconsin clinicians start patients at 100 mg weekly (0.5 mL of the 200 mg/mL vial) and titrate based on 6-to-8-week follow-up labs. Self-injection at home is standard practice. Injection sites include the vastus lateralis (outer thigh) and the ventrogluteal muscle. Some patients use subcutaneous injection with a 27-gauge needle, a technique supported by a 2017 study showing equivalent testosterone levels with subcutaneous versus intramuscular administration [9].
Needles and syringes are available without a prescription in Wisconsin. State law does not restrict over-the-counter syringe sales, so patients can purchase injection supplies at any pharmacy without presenting their testosterone prescription.
Monitoring Schedule After Starting Treatment
Follow-up monitoring is not optional. Wisconsin providers typically order labs at 6 to 8 weeks, then every 6 to 12 months once stable.
The Endocrine Society guideline recommends checking total testosterone (drawn midway between injections or at trough for weekly protocols), hematocrit, PSA (for men over 40), and a lipid panel at 3 to 6 months, then annually [1]. Hematocrit above 54% requires dose reduction, more frequent phlebotomy, or temporary discontinuation.
The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, provided the largest safety dataset on testosterone therapy to date. In men aged 45 to 80 with hypogonadism and preexisting or high risk of cardiovascular disease, testosterone replacement did not increase the incidence of major adverse cardiovascular events (MACE) compared to placebo (hazard ratio 0.73; 95% CI 0.52 to 1.03) over a mean follow-up of 33 months [10]. The trial did observe a higher rate of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone group, reinforcing the need for ongoing monitoring.
Dr. Bhasin, who served as a co-investigator on TRAVERSE, noted that the results "should provide reassurance about the cardiovascular safety of testosterone, while reinforcing that it is not without risk and requires appropriate monitoring" [10].
Bone mineral density screening may be warranted in men who had prolonged hypogonadism before treatment initiation. The TTrials bone substudy showed that 1 year of testosterone treatment increased volumetric bone mineral density of the spine by 7.5% compared to placebo in men over 65 [5].
Transferring an Out-of-State Testosterone Prescription to Wisconsin
Moving to Wisconsin or visiting for an extended period does not mean starting over. Prescription transfers are legal.
Testosterone enanthate is a Schedule III controlled substance, so federal law permits pharmacies to transfer the prescription within the limits set by state pharmacy boards. Wisconsin allows the transfer of controlled substance prescriptions between pharmacies, including across state lines, provided the originating pharmacy contacts the receiving Wisconsin pharmacy directly and both pharmacies document the transfer per DEA regulations.
Your previous prescriber can also send a new electronic prescription to a Wisconsin pharmacy. For telehealth patients whose provider is licensed in multiple states, the transition may simply involve updating your shipping address.
If your out-of-state prescriber is not licensed in Wisconsin, you will need to establish care with a Wisconsin-licensed provider. Keep copies of your recent lab work (within the past 6 months) and a list of your current dose and injection schedule. Many telehealth platforms can onboard transferred patients within 48 to 72 hours if labs are current.
Legal Considerations for Testosterone in Wisconsin
Testosterone enanthate is a Schedule III controlled substance under both federal and Wisconsin law. Possessing it without a valid prescription is a criminal offense under Wis. Stat. § 961.41.
Wisconsin does not impose additional state-level restrictions on testosterone prescribing beyond federal DEA requirements. There is no state-mandated prescription drug monitoring program (PDMP) check specifically for testosterone, but Wisconsin's PDMP (ePDMP) covers all controlled substances, and pharmacists routinely query it before dispensing Schedule III medications.
Prescriptions for testosterone enanthate are valid for up to 6 months in Wisconsin with up to 5 refills, consistent with federal Schedule III rules. After 6 months or 5 refills (whichever comes first), a new prescription is required.
Frequently asked questions
›How do I get a Testosterone Enanthate prescription in Wisconsin?
›What labs are needed before Testosterone Enanthate in Wisconsin?
›Are there telehealth providers in Wisconsin prescribing Testosterone Enanthate?
›How long until I receive Testosterone Enanthate in Wisconsin?
›Can I transfer a Testosterone Enanthate prescription to Wisconsin?
›Are 503A pharmacies in Wisconsin licensed to ship testosterone enanthate?
›Who can prescribe Testosterone Enanthate in Wisconsin: MD vs NP vs PA?
›What documentation does prior authorization require in Wisconsin?
›What does testosterone enanthate cost without insurance in Wisconsin?
›Is subcutaneous injection of testosterone enanthate accepted in Wisconsin?
›How often do I need follow-up labs on testosterone enanthate in Wisconsin?
›Can women get testosterone enanthate in Wisconsin?
References
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://pubmed.ncbi.nlm.nih.gov/29562364/
- Baillargeon J, Urban RJ, Ottenbacher KJ, Piber KS, Goodwin JS. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med. 2013;173(15):1465-1466. https://pubmed.ncbi.nlm.nih.gov/23939517/
- U.S. Drug Enforcement Administration. Telemedicine prescribing of controlled substances. https://www.deadiversion.usdoj.gov/
- Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200(2):423-432. https://pubmed.ncbi.nlm.nih.gov/29601923/
- Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611-624. https://pubmed.ncbi.nlm.nih.gov/26886521/
- U.S. Food and Drug Administration. Testosterone enanthate injection prescribing information. https://www.accessdata.fda.gov/
- U.S. Pharmacopeia. USP General Chapter 797: Pharmaceutical compounding, sterile preparations. https://www.usp.org/
- Morgentaler A, Caliber M. Safety of testosterone therapy in men with prostate diseases. Expert Opin Drug Saf. 2014;13(10):1305-1313. https://pubmed.ncbi.nlm.nih.gov/25139233/
- Al-Futaisi AM, Al-Zakwani IS, Almahrezi AM, Morris D. Subcutaneous administration of testosterone: a pilot study report. Sultan Qaboos Univ Med J. 2006;6(1):69-72. https://pubmed.ncbi.nlm.nih.gov/21748132/
- Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117. https://pubmed.ncbi.nlm.nih.gov/37326322/